Scarica l'app Stockscreener
2.89
0.70%
0.02
Dopo l'orario di chiusura:
2.91
0.02
+0.69%
Precedente Chiudi:
$2.87
Aprire:
$2.88
Volume 24 ore:
92,508
Relative Volume:
1.21
Capitalizzazione di mercato:
$62.56M
Reddito:
-
Utile/perdita netta:
$-12.94M
Rapporto P/E:
-1.0176
EPS:
-2.84
Flusso di cassa netto:
$-13.83M
1 W Prestazione:
-19.50%
1M Prestazione:
-20.17%
6M Prestazione:
-23.34%
1 anno Prestazione:
+50.52%
Intervallo 1D:
$2.70
$3.38
Intervallo di 1 settimana:
$2.67
$3.915
Portata 52W:
$1.61
$7.42
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Nome
Aileron Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN, MA
Confronta ALRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ALRN | 2.89 | 62.56M | 0 | -12.94M | -13.83M | -2.84 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Aileron Therapeutics Inc Borsa (ALRN) Ultime notizie
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Reports Q3 2024 Financial Results - TipRanks
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Yahoo Finance
Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India
Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Keith Johns Joins Allurion's Board Of Directors - MPO-mag
HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer
Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg
Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World
1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat
Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle
Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex
Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device
Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World
Australia's ALS tumbles on subdued half-year forecast - XM
Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat
In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Aileron Therapeutics Inc Azioni (ALRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):